CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 3 enrolled
Drug / intervention
Naltrexone and Bupropion +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03946111
NCT03946111Phase 3Completed
CompareCT.gov

Cognitive-Behavioral and Pharmacologic Treatment of Binge-Eating Disorder and Obesity

Yale University·interventional·Posted May 10, 2019·Updated Jan 9, 2026

In Brief

A Phase 3 clinical trial evaluating Naltrexone and Bupropion and Placebo for Binge-Eating Disorder and Obesity. Completed, enrolled 3 participants across 1 site.

Detailed Summary

This study will test the relative efficacy and effectiveness of the combination of naltrexone and bupropion (NB) medication as a treatment for binge-eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst non-responders to acute treatments, NB medication results in superior outcomes compared with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBinge-Eating Disorder, Obesity
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 10, 2019
Enrollment StartAug 7, 2019
Primary CompletionDec 5, 2024
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 7.1 years ago

Interventions

Naltrexone and Bupropiondrug

Participants randomly assigned to this arm will receive 12 weeks of Naltrexone and Bupropion medication.

Placeboother

Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.